tbuckley/cabot-search huggingface dataset:
Omitted Author Affiliation
Journal: JAMA Neurology (2016)

Michael F. Waters, MD, PhD; Brian L. Hoh, MD; Michael J. Lynn, MS; Hyung-Min Kwon, MD; Tanya N. Turan, MD; Colin P. Derdeyn, MD; David Fiorella, MD, PhD; Anna Khanna, MD; Tiffany O. Sheehan, BSN; Bethany F. Lane, RN; Scott Janis, PhD; Jean Montgomery, RN; Marc I. Chimowitz, MBChB; for the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) Trial Investigators
Cytologic manifestations of cervical and vaginal infections. I. Epithelial and inflammatory cellular changes
Authors: N. B. Kiviat
Journal: JAMA (1985)

We used multiple logistic regression to analyze microbiological and clinical correlates of inflammatory and epithelial cell changes on Papanicolaou-stained cervical smears in patients from a sexually transmitted disease clinic. Among randomly selected patients, increased numbers of histiocytes and polymorphonuclear leukocytes and the presence of transformed lymphocytes were associated with<i>Chlamydia trachomatis</i>infection, while increased lymphocytes were associated with<i>Trichomonas vaginalis</i>infection; minimal squamous atypia was associated with yeast infection; and moderate squamous atypia and koilocytosis were associated with cervical condylomata visualized by colposcopy. Among patients referred for cervicitis,<i>C trachomatis</i>infection was also associated with reactive or atypical metaplastic cells. Distinct inclusions were seen by Papanicolaou smear in only 22% of<i>C trachomatis</i>infections. In randomly selected patients, however, the presence of transformed lymphocytes or increased histiocytes had a sensitivity of 95%, a specificity of 75%, and a positive predictive value of 50% in relation to isolation of<i>C trachomatis</i>, and could therefore be used for selection of patients for confirmatory testing for<i>C trachomatis</i>infection. (<i>JAMA</i>1985;253:989-996)
indexto advertisers
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 163: Regressed Coronary Aneurysm after Kawasaki Disease: What are they hiding? An Optical Coherence Tomography (OCT) study
Authors: Audrey Dionne, Anne Fournier, Ragui Ibrahim, Catherine Gebhard, Nagib Dahdah
Journal: Circulation (2015)

Background: Coronary artery aneurysms (CAA) are a serious complication of Kawasaki disease (KD). Regression of CAA occurs in 50% of the cases on follow up. Actual imaging techniques often described these segments as normal, whereas studies have shown significant endothelial and smooth muscle dysfunction. Method: KD patients scheduled for angiographic follow-up between June 2013 and August 2014 underwent OCT imaging. We compared coronary intimal changes in coronary artery segments with no history of CAA to segments with regressed CAA, and segments with persistent CAA. The intima was measured in sections adjacent to the CAA for the segments with persistent CAA, at the former CAA and adjacent sections for those who regressed, and at various corresponding sections for segments with no history of CAA. Results: OCT was performed on 18 patients at 12.4 ± 5.5 years. Overall 14/18 (77.7%) had a history of CAA. Of those, 7/14 (50.0%) had regressed CAA at time of OCT. Data was analyzed according to echocardiographic and angiographic progress of CAA segments. Accordingly, all 18/18 persistent CAA segments and 11/11 regressed CAA segments had significant intimal hyperplasia, compared to 1/13 with no history of segmental CAA (P&lt;0.001). The intensity of intimal hyperplasia is displayed in Table 1. Conclusion: Despite normal angiographic features, regressed CAA segments displayed significant intimal hyperplasia, similarly to those with persistent CAA. These features may present a risk of adverse coronary events.
Palliation or cure in hypertension
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ulcusproblem und Säurebasengleichgewicht. Eine klinischexperimentelle Studie.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association between Air Pollution and Intrauterine Mortality in Sao Paulo, Brazil
Authors: Luiz A. A. Pereira, Dana Loomis, Gleice M. S. Conceicao, Alfesio L. F. Braga, Rosangela M. Arcas, Humberto S. Kishi, Julio M. Singer, Gyorgy M. Bohm, Paulo H. N. Saldiva
Journal: Environmental Health Perspectives (1998)
Performance of skin biopsies by general practitioners
Authors: R D G James
Journal: BMJ (1991)

Atherosclerosis is a multifaceted chronic inflammatory disease characterized by the accumulation of modified lipoproteins and immune cells in the aortic wall and vascular dysfunction. The uptake of modified low density lipoproteins (mLDL) by MFs plays an important role in atherosclerosis through the modulation of cholesterol metabolism and MF activation. To date, the impact of mLDL on B cell phenotype and functions is unaddressed. We show that B cells can uptake acetylated and oxidized LDL (acLDL and oxLDL, respectively) via a dynamin-dependent pathway in a concentration, time, and temperature-dependent manner. Assessment of the transcriptional profiles of in vivo acLDL+ B cells and acLDL- B cells by RNAseq suggests that acLDL+ B cells assume an anergic like phenotype. Anergy plays an important role in keeping autoreactive B cells in a state of unresponsiveness and the loss of anergy contributes to the development of autoimmune diseases. Currently, nothing is known about the role and regulation of B cell anergy in atherosclerosis. We show here for the first time that GRAIL, an E3 ubiquitin ligase associated with T cell tolerance, is expressed in B cells. To determine whether B cell-specific GRAIL expression plays a role in atherosclerosis, we performed adoptive transfer of GRAIL-deficient or GRAIL-sufficient B cells into B-cell-deficient mice on apolipoprotein-E deficient background (uM<sup>−/−</sup> Apoe<sup>−/−</sup>) mice and examined atherogenesis after 8 weeks of western diet feeding. B cell-specific GRAIL-deficiency supported plaque burden and orchestrated inflammation in the aortic wall. These data suggest that there is a specific mechanism by which B cells recognize mLDL and regulate their anergy-dependent response to mLDL in atherosclerosis.
Children's Exposure Assessment: A Review of Factors Influencing Children's Exposure, and the Data Available to Characterize and Assess That Exposure
Authors: Elaine A. Cohen Hubal, Linda S. Sheldon, Janet M. Burke, Thomas R. McCurdy, Maurice R. Berry, Marc L. Rigas, Valerie G. Zartarian, Natalie C. G. Freeman
Journal: Environmental Health Perspectives (2000)

Atopy is a major risk factor for the development of asthma.Immune processes that lead to the development of antigen-specific IgE are essential to the development of atopy.This review examines the immune processes that are candidate targets for modulation by environmental agents; environmental and lifestyle factors that have been suggested as modulators of the development of atopy; and the impact of known environmental agents on atopic processes in the airway.The most important periods of immune development with regard to expression of atopy are likely during gestation and early childhood.A better understanding of which environmental agents are important, as well as the period of life during which these agents may exert an important effect, is essential to devising rational environmental avoidance strategies for at-risk populations.
A phase I, dose-escalation, multi-center study of PFK-158 in patients with advanced solid malignancies explores a first-in-man inhbibitor of glycolysis.
Authors: Rebecca A. Redman, Paula Raffin Pohlmann, Michael R. Kurman, Gilles Tapolsky, Jason Alan Chesney
Journal: Journal of Clinical Oncology (2015)

TPS2606 Background: In human cancers, activation of the MAP kinase and PI3K/PTEN/AKT pathways converge to increase the expression and activity of a potent regulator of glycolysis, 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase (PFKFB3). This enzyme synthesizes fructose-2,6-bisphosphate (F2,6BP), which is an activator of PFK-1, a key enzyme of glycolysis that is tightly controlled by multiple metabolic feedback mechanisms and dictates the overall rate of glycolytic flux to lactate and the TCA cycle. PFK158 is a potent small molecule inhibitor of PFKFB3 that is selectively cytotoxic to cancer cells and displays broad anti-tumor activity causing significant growth inhibition in preclinical models of breast, lung, glioblastoma, ovarian, pancreatic, melanoma and colon cancer. In addition, because resistance mechanisms frequently activate pathways that result in up-regulation of glycolysis, combination treatments with cytotoxic and targeted agents result in increased efficacy and tumor regressions. Importantly, IND-enabling safety and toxicity studies have demonstrated that PFK158 is well tolerated in rats and dogs resulting in an acceptable pre-clinical therapeutic index. Methods: The primary objective of this phase I clinical trial is to describe the dose limiting toxicity of PFK158 and to determine either the maximum tolerated dose or biological effective dose of PFK-158 in a "3+3" cohort-based dose escalation design that follows a modified Fibonacci scheme. Multiple secondary endpoints have been incorporated to assess the effects of PFK-158 on peripheral blood mononuclear cell F2,6BP activity, and on glucose uptake using FDG-PET imaging. This trial is currently enrolling at four US sites; Cohort 3 (96 mg/m2) has been completed without dose-limiting toxicity and Cohort 4 (168 mg/m2) has been enrolled as of February 2015. In conclusion, PFK158 is a first-in-human and first-in-class PFKFB3 inhibitor that is currently under evaluation in a phase I trial and is expected to have significant clinical utility either as a monotherapy or when combined with other targeted agents. Clinical trial information: NCT02044861.
The physician's role in areawide planning
Authors: J. H. Cavanaugh
Journal: JAMA (1966)

The majority of our population now lives in metropolitan areas, and the hospital and health problems of these areas constitute the problems of physicians, local and state government, national government, and society generally. The ability of physicians to cope with future hospital and related health facility planning problems will depend upon their ability to work towards effective solutions to the many hospital and health planning problems facing the nation today. Is it possible to overcome unrelated, individual, and sometimes selfish action on the part of some physicians and some hospital boards of trustees? Is it possible to attain overall hospital planning at the metropolitan and regional level? Is it possible to develop within the medical profession a vigorous and dedicated leadership that will let those persons responsible for patient care help our cities and metropolitan areas control their destinies? Many believe that it is possible, but that it will require
Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group
Authors: Craig Erker, Benita Tamrazi, Tina Y Poussaint, Sabine Mueller, Daddy Mata-Mbemba, Enrico Franceschi, Alba A Brandes, Arvind Rao, Kellie B Haworth, Patrick Y Wen, Stewart Goldman, Gilbert Vezina, Tobey J MacDonald, Ira J Dunkel, Paul S Morgan, Tim Jaspan, Michael D Prados, Katherine E Warren
Journal: The Lancet Oncology (2020)
Intranasal Surgery.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LEPROSY IN NEW BRUNSWICK.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
RADIOBIOLOGY
Authors: C. Gu, H. Demir, K. Joshi, Y. Nakamura, R. Yamada, S. Gupta, C.-H. Kwon, A. R. Chaudhury, I. Nakano, R. Yong, C. Yang, R. Lonser, Z. Zhuang, H.-S. Gwak, G. H. Jo, O. Bogler, Y.-J. Chwae, H. Yoo, S. H. Lee, J. B. Park, K. Burrell, S. Jelveh, R. Hill, G. Zadeh, B. Mcellin, S. Sirasanagandla, T. Mashimo, S. Nannepaja, V. Vemireddy, S. Burma, R. Bachoo
Journal: Neuro-Oncology (2011)
Abstract CT017: A Phase Ib of a combination of two chimeric (Trastuzumab-like and Pertuzumab-like) HER-2 B cell peptide vaccine emulsified in ISA 720 and nor-MDP adjuvant in patients with advanced solid tumors
Authors: Tanios Bekaii-Saab, Lai Wei, Robert Wesolowski, Daniel Ahn, Christina Wu, Maryam Lustberg, Amir Mortazavi, Bhuvaneswari Ramaswamy, Jay Overholser, Pravin Kaumaya
Journal: Cancer Research (2019)

Abstract Background: HER-2 is a transmembrane receptor that is overexpressed in multiple epithelial tumors. We have previously shown that a first generation HER-2 B-cell peptide vaccine targeting epitopes (628-647) and (316-339) was safe and relatively active. We recently developed a novel B-cell epitope specific vaccine (HER-Vaxx) consisting of epitopes derived from the extracellular domain of HER-2 that correspond to amino acid sequences 597-626 (pertuzumab binding site) and 266-296 (trastuzumab binding site). Methods: This first-in-human Phase 1b study evaluated the safety, optimal immunologic/biologic dose (OID/OBD) and immunogenicity of HER-Vaxx. Using a 3+3 dose escalation design, 3 patients (pts) were treated at each dose level (DL). If &amp;lt;2 pts experience dose-limiting toxicity (DLT), we required an additional 3 pts to be entered at that DL for OID/OBD assessment (defined as the dose level inducing a strong immunogenic response for 5 out of 6 patients). We also required that at least 6 patients at each DL to receive 3 inoculations of the combination vaccines at 3-week intervals and that &amp;lt; 2 of the 6 pts experience DLT before dose escalation. DLs were 1.0 mg (DL1), 1.5 mg (DL2), 2.0 mg (DL3) and 2.5 mg (DL4) of each peptide. Each dose contained 0.025 mg of n-MDP. Results: 49 patients with metastatic and/or recurrent solid tumors and a median of 4 prior lines of chemotherapy received at least one inoculation of HER-vaxx. Common related toxicities include injection site reactions (56% grade 1/2 and 5% grade 3/4). There were no DLTs. The OID/OBD was found to be DL 2 (1.5 mg of each peptide vaccine).A total of 28 patients received ≥ 3 vaccinations including 2 with a partial response and 14 with stable disease. Of those, 6 patients received at least one 6-month boost. The vaccine generated sustained humoral response eliciting HER-2 specific antibodies in the majority of responding patients. Conclusion: We demonstrate that HER-Vaxx is well tolerated and able to generate sustained anti-HER-2 immune response. Given the promise, continuous development of the vaccine is ongoing at the suggested OBD in HER-2 overexpressing tumors. Citation Format: Tanios Bekaii-Saab, Lai Wei, Robert Wesolowski, Daniel Ahn, Christina Wu, Maryam Lustberg, Amir Mortazavi, Bhuvaneswari Ramaswamy, Jay Overholser, Pravin Kaumaya. A Phase Ib of a combination of two chimeric (Trastuzumab-like and Pertuzumab-like) HER-2 B cell peptide vaccine emulsified in ISA 720 and nor-MDP adjuvant in patients with advanced solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT017.
Hepatic arterial infusional (HAI) therapy in patients with unresectable primary liver cancer: Use of dynamic contrast enhanced MRI to evaluate response
Authors: W. R. Jarnagin, L. H. Schwartz, D. H. Gultekin, M. Gönen, D. Haviland, L. H. Blumgart, M. I. D’Angelica, Y. Fong, R. P. DeMatteo, N. E. Kemeny
Journal: Journal of Clinical Oncology (2008)

4597 Background: This study reports the final results of HAI with floxuridine (FUDR) and dexamethasone (Dex) in patients (pts) with unresectable intrahepatic cholangiocarcinoma (ICC) or hepatocellular carcinoma (HCC) and the utility of DCE MRI to predict treatment response. Methods: 34 unresectable pts (26 ICC, 8 HCC) were treated with HAI FUDR/Dex over 14 days on a 4-week cycle. DCE-MRI scans were performed at baseline and at 2-month intervals using a conventional 1.5 Tesla GE scanner. A bolus injection of constant dose Gd- complex contrast agent (0.1 mM/kg) was given and images acquired with temporal resolution of 1 second. Dynamic and pharmacokinetic parameters related to tumor perfusion were analyzed and correlated with response (RECIST) and survival. Results: At a median followup of 35 months (mos), 1- and 2-year survival was 88% and 68%, respectively; median survival was 29 mos. Two pts with HCC responded (25%), and 3 had stable disease; 15 pts with ICC (58%) had partial response, and 10 (38%) had stable disease. One ICC patient subsequently underwent resection. For all patients, median time to progression was 7.4 mos and response duration was 11.9 mos (range 4.1–14.7). Treatment was well-tolerated: grade 3 AST and alkaline phosphatase elevations were seen in 5 (15%) and 4 (12%) pts, respectively. Grade 3/4 bilirubin elevations were seen in 3 pts, but none developed strictures. Preliminary analysis of DCE-MRI data showed the baseline area under the curve at 180 seconds (AUC180), a global assessment of tumor perfusion, was significantly associated with survival (p=0.02, Cox regression). Pts with AUC180 > 0.18 had a median survival of 32 mos versus 19 mos in those with AUC180 < 0.18 (p=0.04). Conclusions: HAI therapy with FUDR + Dex provides an overall response rate of 50% and a median survival of 29 mos in pts with unresectable primary liver cancer. Pretreatment DCE MRI assessment of tumor perfusion characteristics appears to have important prognostic value regarding treatment outcome. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration J & J / Codman